SCHEMBL23371306

SCHEMBL23371306

Cc1cnn(C)c1C(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 3/20 0.37
TSHR P16473 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
SIGMAR1 Q99720 1/20 0.37
GFER P55789 1/20 0.36
PCSK9 Q8NBP7 1/20 0.36
RORC P51449 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
BRD4 O60885 1/20 0.35
BCHE P06276 1/20 0.34
STK17B O94768 1/20 0.34
STK17A Q9UEE5 1/20 0.34
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
ITGA4 P13612 1/20 0.34
ITGB7 P26010 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23366843 0.81 SMN1; SMN2 (0.39) KDM4ELMNAALDH1A1TSHRMAPT
SCHEMBL23354046 0.81 LMNA (0.38) KDM4ELMNAALDH1A1MAPTHPGD
SCHEMBL23384726 0.77 KMT2A (0.46) KDM4ELMNAALDH1A1TSHRSIGMAR1
SCHEMBL23366891 0.76 SMN1; SMN2 (0.35) KDM4ELMNAALDH1A1MAPTHPGD
SCHEMBL24927744 0.76 DYRK1A (0.38) KDM4ELMNAALDH1A1TSHRMAPT
SCHEMBL14417732 0.74 GSK3B (0.44) KDM4ELMNAALDH1A1TSHRHPGD
SCHEMBL23354501 0.73 ALDH1A1 (0.39) KDM4ELMNAALDH1A1TSHRMAPT
SCHEMBL23367065 0.73 KDM4E (0.40) KDM4ELMNAALDH1A1TSHRMAPT
SCHEMBL22911503 0.73 KDM4E (0.40) KDM4ELMNAALDH1A1TSHRMAPT
SCHEMBL28545006 0.71 ALDH1A1 (0.35) KDM4ELMNAALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed
WO-2021094436-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 KDM4E 3062/4885LMNA 1752/4885ALDH1A1 3828/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 KDM4E 3062/4885LMNA 1752/4885ALDH1A1 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.